BioSpace News Archive

CarePoint Health and Rothman Orthopaedic Institute announced a five-year partnership to establish a world-class comprehensive orthopedic services institute at Hoboken University Medical Center and Christ Hospital in Jersey City.

Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations through potential FUROSCIX approval and launch, if approved, and into 2023

Nearly 50 years after its inception, the Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, unveils a rebranded chapter program, “Lulie’s Next Chapter for Light & Vision.”

Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.

The SERIES-5 MyoVision is an FDA-cleared, Class II medical device patented for diagnosing soft tissue injury.

TORONTO, March 23, 2021 /PRNewswire/ - Exact Imaging, the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announces $5.1M in financing provided by BDC Capital, through the Bridge Financing Program, and Export Development Canada.

Frequency Therapeutics, Inc., announced topline, day-90 data from its FX-322 Phase 2a study.

Maze Therapeutics, a company translating genetic insights into new precision medicines, announced that Atul Dandekar, a successful business leader with nearly 25 years of pharmaceutical industry experience, has joined the Company as chief strategy officer.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced the first patient has been dosed in the Phase 2a portion of a Phase 1b/2a clinical trial evaluating NT-I7, a novel T cell amplifier, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® for the treatment of patients with relapsed/refractory advanced solid tumors.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that CEO Chris Bunka is presenting at the Benzinga Biotech Small Cap Conference to be held on March 24-25, 2021.